Impact of HIV Type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs

AIDS Research and Human Retroviruses

Volumn 17, Issue 6, 2001, Pages 487-497

  Kaufmann, Gilbert R ^a   Suzuki, Kazuo ^b   Cunningham, Philip ^b   Mukaide, Motokazu ^c   Kondo, Makiko ^d   Imai, Mitsunobo ^d   Zaunders, John ^b   Cooper, David A ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c SRL INC   (Japan)

^d KANAGAWA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOSIDE DERIVATIVE; PROTEIN P1; PROTEIN P6; PROTEIN P7; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; AMINO TERMINAL SEQUENCE; ANTIBIOTIC THERAPY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; TREATMENT FAILURE; VIROLOGY;

ADULT; AMINO ACID SEQUENCE; BASE SEQUENCE; BINDING SITES; CAPSID; CAPSID PROTEINS; COHORT STUDIES; DNA, VIRAL; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; GENE PRODUCTS, GAG; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; MUTAGENESIS; NUCLEOSIDES; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR; TREATMENT FAILURE; VIRAL PROTEINS;

EID: 0034915565     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220151126526     Document Type: Article

References (31)

1. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-Week follow-up
2. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
3. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens
4. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: Results from a community-based study
5. Safety and efficacy of ritonavir and saquinavir in com- bination with zidovudine and lamivudine
6. Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in the observational cohort of HIV-1-infected individuals
7. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
8. Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy
9. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study
10. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy
11. Baseline HIV drug resistance profile predicts response to ritonavir- saquinavir protease inhibitor therapy in a community setting
12. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed
13. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
14. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
15. Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure
16. Virologic responses to a riton-avir-saquinavir-containing regimen in patients who had previously failed nelfinavir
17. Second locus involved in human 1 immunodeficiency virus type 1 resistance to protease inhibitors
18. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
19. Proline residues in human immunodeficiency virus type 1 p6(Gag) exert a cell type-dependent effect on viral replication and virion incorporation of Pol proteins
20. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1
21. Competitive inhibition of human immunodeficiency virus type-1 protease by the Gag-Pol transframe protein
22. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
23. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
24. Introduction of HIV drug-resistance testing in clinical practice
25. Anti-HIV ef-fect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors
26. Clinical resistance patterns and responses to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced persons
27. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
28. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral experienced patients in advanced stages of HIV-1 infection
29. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
30. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase in-hibitor-sensitive genotype
31. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy